Expert Perspectives: Sequencing Therapy in mCRC: Does Order Matter?

Submitted by onc_editor on Wed, 01/24/2018 - 14:43

Expert Perspectives: Sequencing Therapy in mCRC: Does Order Matter?

 

New insights into the understanding of recent and emerging therapeutic options for patients with mCRC have occurred, including the utilization of tyrosine kinase inhibitors for those patients who have progressed after failing first- and second-line therapies. As these novel therapies are approved, it is critical that clinicians are confident in their understanding of the mechanisms of action of these agents and their roles in mCRC. This roundtable discussion featuring Drs. Gerald Prager, Tanios Bekaii-Saab, and Eric Van Cutsem serves to further clinicians' understanding of the safety and efficacy profiles of these agents, provide insight into how to manage adverse effects, and elucidate how best to incorporate these agents in the appropriate sequence, either in combination or alone, when they are available.